Cyclooxygenase-2 Inhibitor Enhances the Efficacy of a Breast Cancer Vaccine: Role of IDO
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
We report that administration of celecoxib, a specific cyclooxygenase-2 (COX-2) inhibitor, in combination with a dendritic cell-based cancer vaccine significantly augments vaccine efficacy in reducing primary tumor burden, preventing metastasis, and increasing survival. This combination treatment was tested in MMTV-PyV MT mice that develop spontaneous mammary gland tumors with metastasis to the lungs and bone marrow. Improved vaccine potency was associated with an increase in tumor-specific CTLs. Enhanced CTL activity was attributed to a significant decrease in levels of tumor-associated IDO, a negative regulator of T cell activity. We present data suggesting that inhibiting COX-2 activity in vivo regulates IDO expression within the tumor microenvironment; this is further corroborated in the MDA-MB-231 human breast cancer cell line. Thus, a novel mechanism of COX-2-induced immunosuppression via regulation of IDO has emerged that may have implications in designing future cancer vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341 · cited 1×
“Expression of IDO has been observed in cells exposed to PGE2 or IFN- and in certain types of activated macrophages and tolerizing DCs (29, 30, 38, 53, 54).”
BackgroundUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“Originally identified in the placenta, IDO has recently been detected in many cancers including breast cancer, where it has been implicated in immune escape (25, 26, 39).”
BackgroundMuller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064 · cited 1×
“IDO activity is increased under pathological conditions including tumor development (25, 36), and it is overexpressed in many tumors and on tolerizing APCs (25, 26, 29, 37–39).”
Background
Cited by
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 1,035
Structure and Function of the Cell Surface (Tethered) Mucins
Hattrup, C. L., & Gendler, S. J. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100659 · Cited by 779
Self-citationThe parallel lives of angiogenesis and immunosuppression: cancer and other tales
Motz, G. T., & Coukos, G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3064 · Cited by 481
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
Prendergast, G. C., Smith, C., Thomas, S., Mandik-Nayak, L., Laury-Kleintop, L., Metz, R., & Muller, A. J. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1549-4 · Cited by 482
Nanoparticle-Based Immunotherapy for Cancer
Shao, K., Singha, S., Clemente-Casares, X., Tsai, S., Yang, Y., & Santamaria, P. (2015) · ACS Nano · doi:10.1021/nn5062029 · Cited by 470
Cancer prevention and therapy through the modulation of the tumor microenvironment
Casey, S. C., Amedei, A., Aquilano, K., Azmi, A. S., Benencia, F., Bhakta, D., Bilsland, A. E., Boosani, C. S., Chen, S., Ciriolo, M. R., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.007 · Cited by 372
Lipoxygenase metabolism: roles in tumor progression and survival
Pidgeon, G. P., Lysaght, J., Krishnamoorthy, S., Reynolds, J. V., O’Byrne, K., Nie, D., & Honn, K. V. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9098-3 · Cited by 295
Holtan, S. G., Creedon, D. J., Haluska, P., & Markovic, S. N. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60669-1 · Cited by 292
Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses
Vermaelen, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00008 · Cited by 215
“Also, activation of DCs results in IDO expression in these cells and promotes paradoxical induction of T-regs (105).”
BackgroundInfluentialGately, S., & West, R. (2007) · Drug Development Research · doi:10.1002/ddr.20177 · Cited by 178
“, 2003], and in combination with cancer vaccines [Basu et al., 2006; Inoue and Aramaki, 2007].”
BackgroundChambers, E. S., Vukmanovic-Stejic, M., Shih, B. B., Trahair, H., Subramanian, P., Devine, O. P., Glanville, J., Gilroy, D., Rustin, M. H. A., Freeman, T. C., et al. (2021) · Nature Aging · doi:10.1038/s43587-020-00010-6 · Cited by 96
Delivery Strategies for Immune Checkpoint Blockade
Chen, Q., Wang, C., Chen, G., Hu, Q., & Gu, Z. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800424 · Cited by 90
Metadata
- Authors
- Basu, G. D., Tinder, T. L., Bradley, J. M., Tu, T., Hattrup, C. L., Pockaj, B. A., & Mukherjee, P.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-08
- Volume
- 177
- Issue
- 4
- Pages
- 2391-2402
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1669486342
- Cited by
- 132
- References
- 3
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.